trending Market Intelligence /marketintelligence/en/news-insights/trending/fxB63QvJdqMzurpd2QWlRQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aileron Therapeutics files for $69M IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aileron Therapeutics files for $69M IPO

Aileron Therapeutics Inc. filed for an IPO of up to $69.0 million of its common stock.

The company plans to apply for listing of common stock on the Nasdaq Global Market under the symbol ALRN.

Aileron plans to use the net proceeds from the offering to fund ongoing clinical trials of ALRN-6924, to fund additional research and clinical development activity related to ALRN-6924 and other programs, and for working capital and other general corporate purposes.

Merrill Lynch Pierce Fenner & Smith Inc., Jefferies LLC, William Blair & Co. LLC and Canaccord Genuity Inc. are acting as underwriters in the offering.

Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of therapeutics called stapled peptides.